SGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus

Basic Details
Date Posted
Tuesday, March 19, 2019
Status
Complete
Medical Product
canagliflozin
dapagliflozin
empagliflozin
sitagliptin
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Health Outcome(s)
diabetic ketoacidosis
Description

The goal of this request was to estimate rates of diabetic ketoacidosis (DKA) among new users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors canagliflozin, dapagliflozin, empagliflozin, or sitagliptin in the Sentinel Distributed Database (SDD). Data from March 1, 2013 through June 30, 2018 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on November 28, 2018.